UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL,FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE
14A-6(E)(2))
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12
VENTIV HEALTH, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[_] Fee paid previously with preliminary materials.
[_] Checkbox if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
VENTIV HEALTH, INC. REPORTS
THIRD QUARTER RESULTS
Page 2 of 5
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
Notes:
Reg. (S) 240.14a-101.
SEC 1913 (3-99)
VENTIV HEALTH, INC. REPORTS
THIRD QUARTER RESULTS
Page 3 of 4
[LOGO OF VENTIV HEALTH]
Contacts:
Investors/Corporate:
John R. Emery
Chief Financial Officer
(732) 537-4800
investor@ventiv.com
-------------------
VENTIV TO ELECT SIX DIRECTORS AT ANNUAL MEETING
NEW YORK, June 14, 2002 -- Ventiv Health, Inc. (Nasdaq: VTIV), a leading
provider of comprehensive marketing and sales solutions to the pharmaceutical
and life sciences industries, announced today that it will elect six directors
at its 2002 annual meeting rather than seven as indicated in its proxy
statement. Ventiv's 2002 annual meeting is to be held on Wednesday June 19,
2002.
The reduction of directors to be elected has been occasioned by an indication
from one of Ventiv's current directors, Mortimer Zuckerman, that he will be
unable to continue to serve as a director of the company due to conflicting time
demands. Mr. Zuckerman is the Chairman of Boston Properties, Chairman and
Editor-in-Chief of U.S. News & World Report, Chairman and Co-Publisher of the
New York Daily News and Chairman of Applied Graphics Technologies, Inc. Mr.
Zuckerman has served as a director of Ventiv since 1999.
Although the proxy solicited from Ventiv's stockholders permits its Board of
Directors to select an alternate nominee, no alternate nominee has been chosen.
Ventiv will be initiating a search for at least one additional director with
background in the pharmaceutical and life science industries.
Eran Broshy, Chief Executive Officer of Ventiv, said "We thank Mort for his
contributions to Ventiv over the past three years, and appreciate the
conflicting time demands presented by his responsibilities at Boston Properties,
U.S. News & World Report, the New York Daily News and Applied Graphics
Technologies."
About Ventiv Health
Ventiv Health, Inc. is a leading global provider of comprehensive outsourced
marketing and sales solutions for the pharmaceutical and life sciences
industries. The Company works in consultative partnership with clients to
identify strategic goals and develop customized, integrated solutions to
optimize clients' product portfolios. Ventiv Health's market-leading offerings
include: sales force recruitment, training and execution; consulting, analytics
and forecasting; market research and intelligence; strategic and tactical
planning and product and brand management.
VENTIV HEALTH, INC. REPORTS
THIRD QUARTER RESULTS
Page 4 of 4
For almost three decades, Ventiv Health has provided a broad range of innovative
strategic and tactical solutions to clients across the United States and Europe,
including: Abbott Laboratories, Allergan, AstraZeneca, Aventis, Bayer,
Bristol-Myers Squibb, Eli Lilly, Endo Pharmaceuticals, GlaxoSmithKline, Johnson
& Johnson, Merck, Novartis, Pfizer and Pharmacia. For more information on Ventiv
Health, visit www.ventiv.com.
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause Ventiv Health's
performance to differ materially. Such risks include, without limitation:
changes in trends in the pharmaceutical industry or in pharmaceutical
outsourcing; our ability to compete successfully with other services in the
market; our ability to maintain large client contracts or to enter into new
contracts; uncertainties related to future incentive payments and revenue share
agreements; and, our ability to operate successfully in new lines of business.
Readers of this press release are referred to documents filed from time to time
by Ventiv Health, Inc. with the Securities and Exchange Commission for further
discussion of these and other factors.